NATALIE VATINYAN: Open Payments
NPI 1902663842 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,823 in 75 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $1,143 · 2025 $1,823
Food & beverage: $1,655Education: $168
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $813 |
| Janssen Biotech, Inc. | 6 | $245 |
| Ardelyx, Inc. | 10 | $177 |
| Regeneron Healthcare Solutions, Inc. | 4 | $110 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Lilly USA, LLC | 2 | $51 |
| Madrigal Pharmaceuticals | 1 | $36 |
| EVOKE PHARMA, INC. | 2 | $34 |
Products named: RINVOQ, SKYRIZI, IBSRELA, TREMFYA, DUPIXENT, CREON, STELARA, XIFAXAN.
Industry payments across TX — which companies pay providers there.
